Senzime receives large order from leading California University Hospital System
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Uppsala, Sweden, July 20, 2023. Senzime AB (publ), a leader in the field of peri- and post-operative patient monitoring solutions, today announced an initial order from a leading California-based University Hospital System consisting of 70 TetraGraph monitors to be installed over a 9-month period. Initial order value amounts to approximately SEK 1.5 million and the monitors are expected to generate annual recurring revenues in excess of SEK 3 million per year in full use. The order was secured following an extensive clinical evaluation process.
“This is yet another major win for us in the US market and we continue to develop our market position as the leading provider of neuromuscular monitoring solutions. The order is the result of the work of our dedicated team, our commitment to patient safety and our solutions that are perfectly in-line with the new clinical guidelines”, comments Philip Siberg, CEO of Senzime.
The TetraGraph is the first portable electromyography (EMG)-based neuromuscular monitor on the market that is clinically validated and that meets the new clinical guidelines published by ASA (American Society of Anesthesiologists) and ESAIC (European Society of Anaesthesiology and Intensive Care). Since market introduction in 2019, the TetraGraph has been installed at hundreds of leading hospitals across the globe.
The TetraGraph system is used during surgery to accurately monitor the patient’s level of neuromuscular blockade. This helps anesthesiologists secure the right dose of neuromuscular blocking drugs and their antagonists, as well as indicate when it is safe to allow patients to breathe on their own.